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reported in many countries [ 161. Faropenem, having an 
easy route of administration and MICs one or two 
dilutions lower than those of amoxycillin for penicillin- 
susceptible and -resistant pneumococci, is of potential 
interest. If human pharmacokinetic and clinical studm 
support these in vitro results, it may be concluded that 
faropenem, a new oral drug. may play a role in the 
treatment of outpatient respiratory tract infections. It 
may also be employed in follow-up treatment after 
parenteral drug administration following hospital dis- 
charge in a number of infections, including aspiration 
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In recent years the widespread use of fluoroquinolones 
has led to the emergence of fluoroquinolone-resistant 
Staphylococcus aureus, especially among methicillin- 
resistant S. aweus (MRSA) [l]. Three different gene 
loci shown to be involved in quinolone resistance in S. 
aureus have been described. The first is the norA gene 
encoding a membrane-associated active efflux pump 
[2,3]; the second locus includes gyrA andgyrB encoding 
subunits of the DNA gyrase [4-81; and the third 
comprises grlA and grlB encodmg subunits of the DNA 
topoisomerase IV [9-111. Genetic and biochemical 
evidence suggests that for ciprofloxacin the primary 
target in S. aureu~ is the DNA topoisomerase IV and 
not the DNA gyrase [12-141. 
In order to investigate the stability of mutations 
encoding fluoroquinolone resistance within different 
MRSA clones over a period of years, we characterized 
mutations withm the grlA, grlB, gyrA, gyrB and norA 
gene loci and the norA promoter region for 125 MRSA 
clinical isolates from different pathologic sources, 
belonging to three hstinct clonal types determined by 
pulsed-field gel electrophoresis (PFGE). Concomitant 
with this, we also determined the corresponding MIC 
values for each isolate for five different fluoroquinolone 
compounds (ciprofloxacin, ofloxacin, levofloxacin, 
sparfloxacin and moxifloxacin) . 
All isolates were derived from non-repeat clinical 
isolates from different pathologic sources referred to the 
Institute for Medical Microbiology and Virology at the 
University Hospital Diisseldorf‘between 1993 and 1995 
from 11 regional hospitals. During this period, 28 
distinct PFGE types were referred to the institute [15], 
of which the three most common were types 1, 2 and 
3 (comprising 75, 38 and 12 isolates, respectively). 
Together, these isolates comprised the 125 MRSA 
isolates included in this study. PFGE type 1 (75 isolates) 
was isolated between July 1992 and June 1995 from 29 
different units in five different hospitals; PFGE type 2 
(38 isolates) was isolated between November 1992 and 
April 1995 from 19 different wards in three different 
hospitals; PFGE type 3 (12 isolates) was isolated 
between September 1994 and February 1995 from five 
different wards in three different hospitals. Each isolate 
was checked for the presence of the mecA and coa genes 
using a multiplex PCR, which has been described 
previously in order to confirm MRSA status [16]. The 
MIC values for ciprofloxacin, ofloxacin, levofloxacin, 
sparfloxacin and moxifloxacin were determined by a 
broth microdilution method and doubling dilutions of 
test drug ranging from 0.125 to 256 mg/L, with results 
being analyzed after 2 4 h  of incubation at 35°C 
according to NCCLS recommended guidelines [ 171. 
Primer sequences specific for grlA [l  11 (5’-ACTT- 
GAAGATGTTTTAGGTGAT-3‘ and (5’ -TTAGGA- 
AATCTTGATGGCAA-3’), grlB [ l l ]  (5’-CGATT- 
AAAGCACAACAAGCAAG-3 ’ and 5‘-CATCAGT- 
CATAATAATTACTC-3’), gyrA [6] (5’-AATGAA- 
CAAGGTATGACACC-3’ and 5’-TACGCGCTT- 
CAGTATAACGC-3’), gyrB [6] (5’-CAGCGTTA- 
GATGTAGCAAGC-3’ and 5’-CCGATTCCTGT- 
ACCAAATGC-3’), norA [3] (5’-GGTCATTATTA- 
TATTCAGTTGTTG-3‘ and 5‘-GTAAGAAAAAC- 
GATGCTAAT-3’) and the norA promoter region [3] 
(5 ’ -TATGATCAATCCCCTTTAT-3’ and 5’-CTACC- 
AGTTAATCCCAAATCTT-3’) were used to amplify 
genes for subsequent sequencing protocols. Six inde- 
pendent PCR amplifications were carried out using 
a GeneAmp PCR System 2400 (Perkin Elmer, 
Weiterstadt, Germany), and all reagents (GeneAmp 
dNTPs, high-fidelity Taq DNA polymerase and 
X lOPCR buffer) were purchased from Perkin Elmer or 
Boehringer Mannheim (Mannheim, Germany), 
respectively. To prepare cell lysates for use as template 
DNA in PCR, approximately one-tenth of a single 
bacterial colony was picked with a plastic pipette tip 
and mixed in the PCR amplification reaction mixture 
consisting of 10 mM Tris-HC1 (PH 8.3), 50 mh4 KC1, 
2.5 mM MgC12, 100 pM dNTPs, 3 U of high-fidelity 
Taq DNA polymerase and 0.4 pM of the respective 
primers in a final volume of 50 pL. Samples were 
denatured at 94°C for 10 min, followed by 25 
amplification cycles using the following parameters: 
94°C for 20 s, 55°C for 20 s and 72°C for 50 s. A final 
cycle of 72°C for 5 min was used to fully extend 
amplicons. PCR products were purified using a PCR 
purification kit (Qiagen, Hilden, Germany). Amplified 
products were sequenced in both the forward and the 
reverse directions. The reaction was carried out using 
50 ng of DNA, 0.1 pmol of primers, and the Ready 
Reaction Dye Terminator Cycle Sequencing Kit (Perkin 
Elmer), according to the manufacturer’s instructions. 
The products were resolved and automatically analyzed 
using a 310 DNA sequencer (Perlun Elmer). 
MIC values were identical (-+one ddution) for each 
isolate within PFGE clone types 1 and 3, irrespective 
of the time period and location of isolation. For all type 
1 and 3 isolates, the MIC of the least active fluoro- 
quinolone tested, ciprofloxacin, was 16-32 mg/L, 
while that of the most active tested, moxifloxacin, was 
0.5-1.0 mg/L. MIC values of the other quinolones 
tested remained absolutely stable at intermediary 
concentrations (Table 1). 
PFGE type 2 isolates could be divided into two 
groups on the basis of susceptibility to the fluoro- 
quinolones tested. The first four PFGE type 2 isolates, 
isolated in November 1992, remained susceptible to all 
fluoroquinolone compounds tested (Table 1).  In con- 
trast, the following 34 PFGE type 2 isolates (isolated 
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Table 1 Amino acid changes encoded by mutations in the grlA, gyrA, n r B  and norA gene loci in different Staphylococcus 
aureus PFGE-types and the corresponding MIC values of five fluoroquinolones in three different MRSA PFGE types 1, 2 
and 3. No mutations were found in nrlB or in the norA promoter region in any isolate. 
MIC values (mg/L) 
No. of Cipro- Oflox- Levo- Spar- Moxi- 
isolates grL4 W'4 ByrB norA floxacin acin floxacin floxacin floxacin 
PFGE type 1 
75 Ser-80-rPhe Ser-84+Leu None None 16-32 8-16 4-8 2-4 0.5-1 
PFGE type 2" 
4 None None Silent mutation None 0.125 0.125 0.125 50.06 10.06 
(Lys-466+Lys) 




PFGE type 3 
12 Ser-80+Phe Ser-S4+Leu None None 16-32 8 4 4 0.5 
~ ~ ~ 
"PFGE-type 2 isolates fall into two categories based on the time of isolanon, mutations detected in grM, gyrA, gyrB and nor,4 and quinolone 
susceptibility 
between December 1992 and April 1995) showed 
decreased fluoroquinolone susceptibility with MICs 
higher but similar for each isolate (& one dilution) 
within the range 16-32 mg/L for ciprofloxacin and 0.5- 
1.0 mg/L for moxifloxacin. 
Sequence data from each of the genes studied were 
obtained for further analysis. Wild-type sequences with 
no mutations were identified on the basis of being 
identical to the published sequences of grlA and gvlB 
[ I l l ,  gyrA and gyrB [6],  and norA [3]. No mutations 
within the promoter region of norA, grlB or gyrB, with 
the exception of a silent mutation, were found in PFGE 
type 1, 3 and 3 MRSA isolates. All PFGE type 1 and 
PFGE type 3 MRSA, isolated over a period of 3 years 
or 6 months, respectively, showed striking stability over 
time with respect to mutations in the grlA and gyrA 
gene loci and the corresponding phenotypic effect on 
MIC values (Table 1). The Ser-80 + Phe mutation in 
the grlA gene and the Ser-84 + Leu mutation in the 
gyvA gene have been previously described in S. aureus 
[5,6,8,10,11,18]. Within these PFGE type 1 and 3 iso- 
lates, no mutations were found within norA. The first 
four isolates of MRSA PFGE type 2, referred in 
November 1992, had no detectable mutations within 
grlA, gyrA and rwA but a silent mutation in gyvB. The 
subsequent 34 isolates belonging to PFGE type 2 were 
identical with respect to mutations in gvlA (Ser-80 + 
Phe), gyvA (Glu-88 + Lys) and n o d  (Gly-291 + Asp) 
and a silent mutation in gyrA, as well as the silent 
mutation in gyrB also observed in the first four type 2 
isolates (Table 1). The increase in MICs for each of 
the fluoroquinolone compounds tested corresponded 
precisely with the appearance of mutations within gyrA 
and grlA, remaining absolutely conserved in these 34 
isolates, isolated over a period of 2.5 years. The four 
sensitive isolates were derived from three different 
hospitals. Resistant PFGE type 2 isolates were subse- 
quently derived from each of these hospitals, suggesting 
parallel evolution from the original sensitive clone. 
Intermediately resistant isolates with a single mutation 
ingrlA alone or ingyrA alone were not detected. There 
are a number of possible explanations for this. It is 
possible that isolates were missed during sampling as 
only one isolate per patient was studied. A previous 
study characterizinggyr andgrl gene loci in 116 clonally 
unrelated S. aureus isolates only found two such isolates 
with mutations only in gvlA [19], supporting the 
evidence that intermediately resistant isolates are 
unstable [13,19]. 
Previous work has shown that the mutation ingrlA, 
Ser-80+ Phe, in combination with mutations in g y d ,  
either Ser 84+Leu or Glu 88+Lys, confers a similar 
decrease in susceptibility to ciprofloxacin [19]. Addition- 
ally, mutations in norA have a negligible effect on 
quinolone resistance [20]. Thus, although mutations 
between PFGE types 1, 2 (34 ciprofloxacin-resistant 
strains) and 3 are different, they confer similar levels of 
quinolone resistance. 
The conserved mutations within the gene loci 
tested conferring reduced susceptibility to the fluoro- 
quinolone compounds tested, and the concomitant 
conserved MIC values between isolates within the same 
PFGE type over time, and from quite diverse clinical 
environments, are striking. Bearing in mind the wide 
variation in quinolone usage among the 29 units within 
the five different hospitals from which the isolates 
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originated (data not shown), one would perhaps expect 
to see mutations being lost or gained within the genes 
potentially affecting quinolone susceptibility. The 
stability of mutations in genes known to be associated 
with fluoroquinolone resistance, and the stable MIC 
values in clonally related MRSA isolates over time, have 
important implications for quinolone resistance in S. 
aureus. From this study of clinical MRSA isolates, it 
seems likely that once acquired, mutations and the 
decreased susceptibility to quinolones that they confer 
are highly stable, suggesting that the high prevalence of 
fluoroquinolone resistance that we are experiencing 
today in some parts of the world will remain. 
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